Vytrus Biotech has continued its ascent since becoming part of the public market. One year after debuting in SME market segment BME Growth, the company reports solid growth indicators and growing liquidity that support its strategic trajectory. Vytrus Biotech closes 2022 with record revenue and a notable rise in profitability. The company specializes in active ingredients derived from plant stem cells designed for the cosmetic industry. 2022 brought a turnover of 3.7 million euros, up 31 percent from 2021, with a net profit of 605,000 euros.
The year also marks the sixth successive year of robust top-line expansion, averaging over 30 percent growth, even after accounting for a 65 percent increase in revenue observed in 2021. This pattern of sustained expansion underscores the strength of Vytrus Biotech’s business model and its capacity to scale in challenging economic conditions.
Co-founder and chief operating officer Albert Jane commented that surpassing 30 percent growth in both sales and profits in a difficult financial year validates the company’s momentum and scalable business model. The executive highlighted the company’s ongoing commitment to innovation and operational efficiency as key drivers of this performance.
As outlined in Vytrus Biotech’s official statement, the company expanded its geographic footprint to five continents. Overseas sales accounted for 66 percent of total revenue, signaling a strong global demand for its advanced cosmetic ingredients. The same communication notes that Vytrus Biotech celebrated the issuance of three new patents across Europe, the United States, and Japan, reinforcing its leadership in cosmetic science and its capacity to set industry trends through pioneering technologies. Oscar Fair, co-founder and director, emphasized the strategic importance of protecting intellectual property while continuing to push forward with market-leading solutions.
stock growth
In the stock market, Vytrus Biotech has delivered notable gains. During its first nine months as a listed entity, the company’s market capitalization rose from 12 million euros to 24 million euros. Ownership remains concentrated among the founders and select private investors, with significant positions held by Zamit Capital Fund (7.9 percent), the Catalan Institute of Finance (6.2 percent), and Julia Perfumery Group (5.4 percent). In effect, private individuals and smaller investors hold around 40 percent of the company, underscoring broad investor interest in Vytrus Biotech’s growth story.
Market sentiment toward Vytrus Biotech has remained supportive, even amid broader volatility in global stock markets. The progressive strengthening of share value reflects a positive reception from investors who recognize the company’s long-term potential. The company continues to demonstrate resilience and a clear path to value creation for its shareholders in a volatile economic environment. (Source: Vytrus Biotech annual disclosures, 2022).